Cloxacillin sodium monohydrate

SKU: orb1224175

Description

Cloxacillin sodium (Cloxacap) is a sodium salt of cloxacillin that is a penicillinase-resistant, acid resistant, semi-synthetic penicillin. Cloxacillin sodium exerts a bactericidal action against susceptible microorganisms during the stage of active multiplication. Cloxacillin sodium acts through the inhibition of biosynthesis of cell wall mucopeptides.(In Vitro):Cloxacillin sodium monohydrate (0-2048 μg/mL; 20-24 h) shows good antibacterial activity for S. aureus 8325-4 and DU1090 with MIC values both of 0.125 μg/mL.Cloxacillin sodium monohydrate (0.015625 μg/mL; 6 h) inhibits the hemolytic activity of Hlα in vitro, and this inhibition is not only more pronounced when combined with TZ and TZ, but also suppresses the inflammatory response by inhibiting the activation of MAPKs, NF-кB and NLRP3-related proteins.(In Vivo):Cloxacillin sodium monohydrate (1.6125 mg/kg; s.c.; 12-h intervals for 72 h) protects mice from S. aureus peritonitis in vivo when combines with Thioridazine and Tetracycline.Cloxacillin sodium monohydrate (7.5 mg/per; i.p.; twice daily from day 3 for 3 days) develops less severe synovitis and reduces bone erosions when combines with anti-IL-15 antibodies.

Research Area

Pharmacology & Drug Discovery

Key Properties

• CAS Number: 7081-44-9
• MW: 475.88
• Purity: >98% (HPLC)
• Formula: C₁₉H₁₇ClN₃NaO₅S·H₂O
• SMILES: CC1=C(C(=NO1)C2=CC=CC=C2Cl)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)[O-].O.[Na+]
• Target: Others
• Solubility: Ethanol: 25 mg/mL (52.53 mM); Water: 55 mg/mL (115.57 mM); DMSO: 55 mg/mL (115.57 mM)

Bioactivity

• In Vivo:
  Cloxacillin sodium monohydrate (1.6125 mg/kg; s. c. ; 12-h intervals for 72 h) protects mice from S. aureus peritonitis In vivo when combines with Thioridazine and Tetracycline. Cloxacillin sodium monohydrate (7.5 mg/per; i.p.; twice daily from day 3 for 3 days) develops less severe synovitis and reduces bone erosions when combines with anti-IL-15 antibodies. Animal model: Female BALB/c mice (6-week-old; peritonitis model). Dosage: 1.6125 mg/kg (combines with TC (3.125 mg/kg) and TZ (25 mg/kg)). Administration: Subcutaneous injection; 12-h intervals for 72 h. Result: Reduced the degree of inflammatory cell infiltration in the mouse lung tissue and alveolar structures tended to be normal. Significantly reduced the pathological changes in spleen and liver tissue, as well as decreased the CFU counts of S. aureus in the peritoneal cavity. Animal model: Female wildtype C57BL/6 mice (8-week-old; systemic S. aureus-induced arthritis model). Dosage: 7.5 mg/per (combines with 25 μg/per anti-IL-15 antibodies). Administration: Intraperitoneal injection; twice daily from day 3 (after bacterial inoculation) and stopped at day 6. Result: Showed activities of reducing severe synovitis and bone erosions when combined with anti-IL-15 antibodies.
• In Vitro:
  Cloxacillin sodium monohydrate (0-2048 μg/mL; 20-24 h) shows good antibacterial activity for S. aureus 8325-4 and DU1090 with MIC values both of 0.125 μg/mL. Cloxacillin sodium monohydrate (0.015625 μg/mL; 6 h) inhibits the hemolytic activity of Hlα in vitro, and this inhibition is not only more pronounced when combined with TZ and TZ, but also suppresses the inflammatory response by inhibiting the activation of MAPKs, NF-кB and NLRP3-related proteins. Cell Viability Assay Cell line: S. aureus 8325-4, S. aureus DU1090 (an Hlα-deleted strain) Concentration: 0-2048 μg/mL. Incubation time: 20-24 h. Result: Inhibited S. aureus 8325-4 and DU1090 with MIC values both of 0.125 μg/mL.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Quick Database Links

Gene Symbol

Others